

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*. The statements indicating action and use are based largely on information supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will neither be revised nor included in the Cumulative Lists of INNs.

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

Il est notifié que, conformément aux dispositions de l'article 3 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*. Les mentions indiquant les propriétés et les indications des substances sont fondées sur les renseignements communiqués par le fabricant. Elles ne visent qu'à donner une idée de l'utilisation potentielle des nouvelles substances au moment où elles sont l'objet de propositions de DCI. L'OMS n'est pas en mesure de confirmer ces déclarations ni de faire de commentaires sur l'efficacité du mode d'action ainsi décrit. En raison de leur caractère provisoire, ces informations ne figureront pas dans les listes récapitulatives de DCI.

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

De conformidad con lo que dispone el párrafo 3 del "Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas", se comunica por el presente anuncio que las denominaciones detalladas en las páginas siguientes están sometidas a estudio por la Organización Mundial de La Salud como Denominaciones Comunes Internacionales Propuestas. La inclusión de una denominación en las listas de las DCI Propuestas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*. Las indicaciones sobre acción y uso que aparecen se basan principalmente en la información facilitada por los fabricantes. Esta información tiene por objeto dar una idea únicamente de las posibilidades de aplicación de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS no está facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la acción que se atribuye al producto. Debido a su carácter provisional, esos datos descriptivos no deben incluirse en las listas recapitulativas de DCI.

## Proposed International Nonproprietary Names: List 85

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 85 Proposed INN not later than 31 January 2002**.

## Dénominations communes internationales proposées: Liste 85

Des observations ou des objections formelles à l'égard des dénominations proposées peuvent être adressées par toute personne au Programme des Dénominations communes internationales de l'Organisation mondiale de la Santé dans un délai de quatre mois à compter de la date de leur publication dans *WHO Drug Information*, c'est à dire pour la **Liste 85 de DCI Proposées le 31 janvier 2002 au plus tard**.

## Denominaciones Comunes Internacionales Propuestas: Lista 85

Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de Denominaciones Comunes Internacionales de la Organización Mundial de la Salud, en un plazo de cuatro meses, contados desde la fecha de su publicación en *WHO Drug Information*, es decir, para la **Lista 85 de DCI Propuestas el 31 de enero de 2002 a más tardar**.

<i>Proposed INN (Latin, English, French, Spanish)</i>	<i>Chemical name or description: Action and use: Molecular formula Chemical Abstracts Service (CAS) registry number: Graphic formula</i>
<i>DCI Proposée</i>	<i>Nom chimique ou description: Propriétés et indications: Formule brute Numéro dans le registre du CAS: Formule développée</i>
<i>DCI Propuesta</i>	<i>Nombre químico o descripción: Acción y uso: Fórmula empírica Número de registro del CAS: Fórmula desarrollada</i>

### acidum gadocoleticum

gadocoletic acid


trihydrogen [3β-[[[(4S)-4-[bis[2-[bis[(carboxy-κO)methyl]amino-κM]ethyl]amino-κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]]=gadolate(3-)]  
*diagnostic agent*

acide gadocolétique

trihydrogène[3β-[[[(4S)-4-[bis[2-[bis[(carboxy-κO)méthyl]amino-κM]éthyl]amino-κN]-4-(carboxy-κO)butanoyl]amino]-12α-hydroxy-5β-cholan-24-oato(6-)]]=gadolate(3-)]  
*produit à usage diagnostique*

ácido gadocolético

trihidrógeno[3β-[[[(4S)-4-[bis[2-[bis[(carboxi-κO)metil]amino-κM]etil]amino-κN]-4-(carboxi-κO)butanoil]amino]-12α-hidroxi-5β-colan-24-oato(6-)]]=gadolinato(3-)]  
*agente de diagnóstico*



**afeletecanum**

afeletecan

camptothecin, ester with *N*-[[*p*-[(3-*O*-methyl- $\alpha$ -*L*-fucopyranosyl)oxy]phenyl]=thiocarbamoyl]-*L*-histidyl-*L*-valine  
*antineoplastic*

afélétecán


(2*S*)-2-[[[(2*S*)-3-(1*H*-imidazol-4-yl)-2-[[[[4-[(3-*O*-méthyl-6-désoxy- $\alpha$ -*L*-galactopyranosyl)oxy]phényl]amino]thiocarbonyl]amino]propanoyl]amino]-3-méthylbutanoate de (4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle  
*antinéoplasique*

afeletecán

éster de la camptotecina con *N*-[[*p*-[(3-*O*-metil- $\alpha$ -*L*-fucopiranosil)oxi]fenil]=tiocarbamoil]-*L*-histidil-*L*-valina  
*antineoplásico*

C<sub>45</sub>H<sub>49</sub>N<sub>7</sub>O<sub>11</sub>S

215604-75-4

**alfimeprasum**

alfimeprase

[3-*L*-serine]fibrolase-(3-203)-peptide (fibrolase : fibrinolytic enzyme isolated from *Agkistrodon conrix conrix* venom)  
*antithrombotic*

alfiméprase

[3-*L*-sérine]fibrolase-(3-203)-peptide (fibrolase : enzyme fibrinolytique extraite de venin d'*Agkistrodon conrix conrix*)  
*antithrombotique*

alfimeprasa

[3-*L*-serina]fibrolasa-(3-203)-péptido (fibrolasa : enzime fibrinolítica extraída de veneno de *Agkistrodon conrix conrix*)  
*antithrombótico*

C<sub>985</sub>H<sub>1541</sub>N<sub>285</sub>O<sub>301</sub>S<sub>12</sub>

259074-76-5


SFPQRYVQ	LVIVADHRMN	TKYNGDSDKI	RQWVHQIVNT
INEIYRPLNI	QFTLVGLEIW	SNQDLITVTS	VSHDTLASFG
NWRETDLLRR	QRHDNAQLLT	AIDFDGDTVG	LAYVGGMCQL
KHSTGVIQDH	SAINLLVALT	MAHELGHNLG	MNHDGNQCHC
GANSVCVMAAM	LSDQPSKLFS	DCSKKDYQTF	LTVNNPQCIL
NKP			

**alicaforsenum**

alicaforsen  
 2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioadenylyl-(3'→5')-  
 2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 (*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-  
 (*R*)-*P*-thioguanylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-  
 (*R*)-*P*-thioadenylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-  
 thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-  
 thioguanylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-deoxy-(*R*)-*P*-thiocytidylyl-  
 (3'→5')-2'-deoxyadenosine nonadecasodium salt  
*antisense phosphorotioate oligonucleotide*

alicaforsen  
 2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioadénylyl-(3'→5')-  
 2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-  
 (*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-  
 (*R*)-*P*-thioguanylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-  
 (*R*)-*P*-thioadénylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-  
 thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-thiocytidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-  
 thioguanylyl-(3'→5')-(*R*)-*P*-thiothymidylyl-(3'→5')-2'-désoxy-(*R*)-*P*-  
 thiocytidylyl-(3'→5')-2'-désoxyadénosine nonadécasodique  
*inhibiteur de la synthèse de la protéine d'adhésion ICAM-1*

alicaforseno  
 2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-  
 (*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-  
 tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-2'-desoxi-(*R*)-*P*-  
 tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-  
 2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-  
 2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tioadenilil-(3'→5')-(*R*)-*P*-  
 tiotimidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxi-(*R*)-*P*-tiocitidilil-  
 (3'→5')-2'-desoxi-(*R*)-*P*-tioguanilil-(3'→5')-(*R*)-*P*-tiotimidilil-(3'→5')-2'-desoxi-  
 (*R*)-*P*-tiocitidilil-(3'→5')-2'-desoxiadenosina nonadecasódica  
*cadena complementaria (oligonucleótido fosforotioato)*




185229-68-9

**alilusemum**

alilusem  
 7-chloro-1-(2-methylbenzoyl)-2,3-dihydroquinolin-4(1*H*)-one (*E*)-*O*-  
 sulfoxime  
*diuretic*

alilusem  
 (*E*)-*O*-sulfoxime de 7-chloro-1-(2-méthylbenzoyl)-2,3-dihydroquinoléin-  
 4(1*H*)-one  
*diurétique*

alilusem  
 (*E*)-*O*-sulfoxima de 7-cloro-1-(2-metilbenzoil)-2,3-dihidroquinolin-4(1*H*)-ona  
*diurético*



144506-11-6

**ambrisentanum**


ambrisentan

(+)-(2*S*)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-3,3-diphénylpropanoïque  
acid*endothelin receptor antagonist*


ambrisentan

(+)-acide (2*S*)-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3-méthoxy-3,3-diphénylpropanoïque*antagoniste du récepteur de l'endothéline*


ambrisentan

(+)-ácido (2*S*)-2-[(4,6-dimetilpirimidin-2-il)oxi]-3-metoxi-3,3-difenilpropanoico*antagonista del receptor de endotelina*

177036-94-1

**amdoxovirum**

amdoxovir

[(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]methanol  
*antiviral*


amdoxovir

[(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-yl)-1,3-dioxolan-2-yl]méthanol  
*antiviral*

amdoxovir

[(2*R*,4*R*)-4-(2,6-diamino-9*H*-purin-9-il)-1,3-dioxolan-2-il]metanol  
*antiviral*

145514-04-1



**amelubantum**



ethyl [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]benzyl]=oxy]phenyl](imino)methyl]carbamate  
*leukotriene receptor antagonist*

amélubant

[[4-[[3-[[4-[1-(4-hydroxyphényl)-1-méthyléthyl]phénoxy]méthyl]benzyl]oxy]=phényl](imino)méthyl]carbamate d'éthyle  
*antagoniste du récepteur des leucotriènes*

amelubant

[[4-[[3-[[4-[1-(4-hidroxiifenil)-1-metiletil]fenoksi]metil]benzil]oksi]fenil](imino)metil]=carbamato de etilo  
*antagonista del receptor de leucotrienos*

**amotosalenum**

amotosalen 3-[(2-aminoethoxy)methyl]-2,5,9-trimethyl-7H-furo[3,2-g][1]benzopyran-7-one  
*photochemical therapy*

amotosalène


3-[(2-aminoéthoxy)méthyl]-2,5,9-triméthyl-7H-furo[3,2-g][1]benzopyran-7-one  
*photochimiothérapie*

amotosaleno

3-[(2-aminoetoxi)metil]-2,5,9-trimetil-7H-furo[3,2-g][1]benzopiran-7-ona  
*terapia fotoquímica*



161262-29-9

**bimatoprostum**

bimatoprost (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide  
*antiglaucoma*

bimatoprost


(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phénylpent-1-ényl]cyclopentyl]-N-éthylhept-5-énamide  
*antiglaucomateux*

bimatoprost

(Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-[(1E,3S)-3-hidroxi-5-fenilpent-1-enil]ciclopentil]-N-etilhept-5-enamida  
*antiglaucoma*

$C_{25}H_{37}NO_4$ 

155206-00-1

**caldaretum**

caldaret

5-methyl-2-(piperazin-1-yl)benzenesulfonic acid  
*cardiac stimulant*


caldaret

acide 5-méthyl-2-(pipérazin-1-yl)benzènesulfonique  
*cardiotonique*

caldaret

ácido 5-metil-2-(piperazin-1-il)benzenosulfónico  
*cardiotónico* $C_{11}H_{16}N_2O_3S$ 

133804-44-1

**cipralisantum**

cipralisant

4-[(1*R*,2*R*)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1*H*-imidazole  
*histamine- $H_3$  receptor antagonist*


cipralisant

4-[(1*R*,2*R*)-2-(5,5-diméthylhex-1-ynyl)cyclopropyl]-1*H*-imidazole  
*antagoniste des récepteurs  $H_3$  de l'histamine*

cipralisant

4-[(1*R*,2*R*)-2-(5,5-dimetilhex-1-inil)ciclopropil]-1*H*-imidazol  
*antagonista de los receptores  $H_3$  de la histamina* $C_{14}H_{20}N_2$ 

213027-19-1



**dalbavancinum**

dalbavancin

5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]-b-d-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl]carbamoyle]-42-O-a-d-mannopyranosyl-15-N-methyl(ristomycin A aglicone)  
*antibiotique*

dalbavancine


acide 2-désoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dichloro-38-[[3-(diméthylamino)propyl]carbamoyle]-6,11,34,40,44-pentahydroxy-42-(a-d-mannopyranosyloxy)-15-(méthylamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tétradécahydro-20,23:30,33-diéthéno-3,18:35,48-bis(iminométhano)-1H,15H-4,8:10,14:25,28:43,47-tétraméthéno-34H-[1,14,6,22]dioxadiazacyclooctacosino[4,5-m][10,2,16]benzoxadiazacyclotétracosén-56-yl]-2-[(10-méthylundécanylo)amino]-b-d-glucopyranuronique  
*antibiotique*

dalbavancina

ácido 1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dicloro-38-[[3-(dimetilamino)propil]carbamoil]-6,11,34,40,44-pentahidroxi-42-(α-D-manopiranosiloxi)-15-(metilamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahidro-20,23:30,33-dieteno-3,18:35,48-bis(iminometano)-1H,15H-4,8:10,14:25,28:43,47-tetrameteno-34H-[1,14,6,22]dioxadiazaciclooctacosino[4,5-m][10,2,16]=benzoxadiazaciclotetracosen-56-il]-2-[(10-metilundecanoil)amino]-2-desoxi-β-D-glucopiranurónico  
*antibiótico*

C<sub>88</sub>H<sub>100</sub>Cl<sub>2</sub>N<sub>10</sub>O<sub>28</sub>

171500-79-1





**darbeпоetinum alfa**

darbeпоetin alfa

[30-L-asparagine,32-L-threonine,87-L-valine,88-L-asparagine,  
90-L-threonine]erythropoietin (human)  
*antianaemic*

darbépoétine alfa

[30-L-asparagine,32-L-thréonine,87-L-valine,88-L-asparagine,  
90-L-thréonine]érythropoïétine humaine  
*antianémique*

darbeпоetina alfa

[30-L-asparagina,32-L-treonina,87-L-valina,88-L-asparagina,  
90-L-treonina]eritropoietina humana  
*antianémico*

$$C_{800}H_{1300}N_{228}O_{243}S_5$$

209810-58-2

APRLICDSR	VLERYLLEAK	EAENITTCGN	ETCSLNENIT
VPDTKVNFYA	WKRMEVGQQA	VEVWQGLALL	SEAVLRGQAL
LVNSSQVNET	LQLHVDKAVS	GLRSLTTLR	ALGAQKEAIS
PPDAASAAPL	RTITADTFRK	LFRVYSNFLR	GKCLKLYTGEA
CRTGD			

**drotrecoginum alfa**

drotrecogin alfa


blood coagulation factor XIV (human)  
*anticoagulant*

drotrecogine alfa

facteur XIV humain de coagulation sanguine  
*anticoagulant*

drotrecogina alfa

factor XIV de coagulación sanguínea (humano)  
*anticoagulante*





98530-76-8

```

ANSFLJLLRH  SSLJRJCIJJ  ICDFJJAkJI  FQNVDDTLAF
WSKHVDGDQC  LVLPLEHPCA  SLCCGHGTCT  BGIGSFSCDC
RSGWEGRFCQ  REVSFL*NC*SL  DNGGCTHYCL  EEVWRRCS*C
APGYKLGDDL  LQCHPAVKFP  CGRPWKRMEK  KRSHL
DTE
DQEDQVDPRL  IDGKMTRRGD  SPWQVVLDS  KKKLACGAVL
IHPSWVLTA*A  HCMDESKLL  VRLGEYDLRR  WEKWELDLDI
KEVFVHPNYS  KSTTDNDIAL  LH*LAQPATLS  QTIVPICLPD
SGLAERELN*Q  AGQETLVTGW  GYHSSREKEA  KR*NRTFVLNF
IKIPVVP*HNE  CSEVMSNMVS  ENMLCAGILG  DRQDACEGDS
GGPMVASFHG  TWFLVGLVSW  GEGCGLLHNY  G*VYTKVSRYL
DWIHGHIRDK  EAPQKSWAP

```

\* glycosylation sites  
 \* sites de glycosylation  
 \* posiciones de glicosilación

**ecalcidenum**

ecalcidene

1-[(5Z,7E,20S)-1 $\alpha$ ,3 $\beta$ -dihydroxy-9,10-secochola-5,7,10(19)-trien-24-oyl]piperidine  
*antipsoriatie*

écalcidène


1-[(5Z,7E,20S)-1 $\alpha$ ,3 $\beta$ -dihydroxy-9,10-sécochola-5,7,10(19)-trién-24-oyl]pipéridine  
*antipsoriasique*

ecalcideno

1-[(5Z,7E,20S)-1 $\alpha$ ,3 $\beta$ -dihidroxi-9,10-secocola-5,7,10(19)-trien-24-oil]piperidina  
*antipsoriásico*

$C_{29}H_{45}NO_3$ 

150337-94-3

**efalizumabum**

efalizumab

immunoglobulin G1, anti-(human antigen CD11a) (human-mouse monoclonal hu1124  $\gamma$ 1-chain), disulfide with human-mouse monoclonal hu1124 light chain, dimer

*immunomodulator*

éfalizumab

immunoglobuline G1, anti-(antigène CD11a humain) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de souris humanisé hu1124), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris humanisé hu1124

*immunomodulateur*

efalizumab

immunoglobulina G1, anti-(antígeno CD11a humano) (cadena  $\gamma$ 1 del anticuerpo monoclonal humanizado de ratón hu1124), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón hu1124

*immunomodulador*

214745-43-4

**enfuvirtidum**

enfuvirtide

acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-seryl-L-glutaminyll-asparaginyll-glutaminyll-glutaminyll- $\alpha$ -glutamyl-L-lysyl-L-asparaginyll- $\alpha$ -glutamyl-L-glutaminyll- $\alpha$ -glutamyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-asparaginyll-tryptophyl-L-phenylalaninamide

*antiviral*

enfuvirtide


acétyl-L-tyrosyl-L-thréonyl-L-séryl-L-leucyl-L-isoleucyl-L-histidyl-L-séryl-L-leucyl-L-isoleucyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-séryl-L-glutaminyll-asparaginyll-glutaminyll-glutaminyll- $\alpha$ -glutamyl-L-lysyl-L-asparaginyll- $\alpha$ -glutamyl-L-glutaminyll- $\alpha$ -glutamyl-L-leucyl-L-leucyl-L- $\alpha$ -glutamyl-L-leucyl-L- $\alpha$ -aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-séryl-L-leucyl-L-tryptophyl-L-asparaginyll-tryptophyl-L-phénylalaninamide

*antiviral*


enfuvirtida

acetil-L-tirosil-L-treonil-L-seril-L-leucil-L-isoleucil-L-histidil-L-seril-L-leucil-L-isoleucil-L- $\alpha$ -glutamil-L- $\alpha$ -glutamil-L-seril-L-glutaminil-L-asparaginitil-L-glutaminil-L-glutaminil-L- $\alpha$ -glutamil-L-lisil-L-asparaginitil-L- $\alpha$ -glutamil-L-glutaminil-L- $\alpha$ -glutamil-L-leucil-L-leucil-L- $\alpha$ -glutamil-L-leucil-L- $\alpha$ -aspartil-L-lisil-L-triptofil-L-alanil-L-seril-L-leucil-L-triptofil-L-asparaginitil-L-triptofil-L-fenilalaninamida

*antiviral*



159519-65-0

**epafipasum**

epafipase


2-acetyl-1-alkyl-*sn*-glycero-3-phosphocholine deacetylase-(6-400)-peptide (human)  
*antiallergic, antiasthmatic*

épafipase

désacétylase-(6-400)-peptide (humaine) de la 2-acétyl-1-alkyl-*sn*-glycéro-3-phosphocholine  
*antiallergique, antiasthmaticque*

epafipasa

1-O-alkil-2-acetil-*sn*-glicero-3-fosfocolina 6-400-desacetilasa (humana)  
*antialérgico, antiasmático*



208576-22-1

AAASFGQTKI	PRGNPYSVG	CTDLMFDHTN	KGTFRLRYYP
SQDNDRDLDTL	WIPNKEYFWG	LSKFLGTHWL	MGNILRLLFG
SMTTPANWNS	PLRPGEKYPL	VVFSHGLGAF	RTLYSAIGID
LASHGFIVAA	VEHRDRSASA	TYYFKDQSAA	EIGDKSWLYL
RTLKQEEETH	IRNEQVRQRA	KECSQALSLI	LDIDHGKPKV
NALDLKFDME	QLKDSIDREK	IAVIGHSFGG	ATVIQTLSKD
QRFRCGIALD	AWMFPLGDEV	YSRIPQPLFF	INSEYFQYPA
NI IKMKKCYC	PKERKMITI	RGSVHQNFAD	FTFATGKIIG
HMLKLGKGDID	SNVAIDL SNK	ASLAF LQKHL	GLHKDFDQWD
CLIEGDDENL	IPGTNINTTN	QHIMLQNSSG	IEKYN

**epoetinum delta**

epoetin delta

1-165-erythropoietin (human HMR4396), glycoform δ  
*antianaemic*

époétine delta

1-165-érythropoïétine (humaine HMR4396), glycoforme δ  
*antianémique*

epoetina delta

1-165-eritropoietina (humana HMR4396), glicofoma δ  
*antianémico*

$C_{609}H_{1301}N_{229}O_{240}S_5$ 

261356-80-3

APPRLICDSR	VLERYLLEAK	EAENITTGCA	EHCSLNE <sup>*</sup> IT
VPDTKVN <sup>*</sup> FYA	WKRMEVGQQA	VEVWQGLALL	SEAVLRGQAL
LVN <sup>*</sup> SSQPWEP	LQLHV <sup>*</sup> DKAVS	GLRSLTLLR	ALGAQKEAIS
PPDAAS <sup>*</sup> AAPL	RTITAD <sup>*</sup> FRK	LFRVYSN <sup>*</sup> FLR	GKLKLYTGEA
CRTGD			

\* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

**erlosamidum**

erlosamide

(2*R*)-2-(acetylamino)-*N*-benzyl-3-methoxypropanamide  
*anticonvulsant*


erlosamide

(2*R*)-2-(acétylamino)-*N*-benzyl-3-méthoxypropanamide  
*anticonvulsivant*

erlosamida

(2*R*)-2-(acetilamino)-*N*-bencil-3-metoxipropanamida  
*anticonvulsivo* $C_{13}H_{18}N_2O_3$ 

175481-36-4

**erlotinibum**

erlotinib

*N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine  
*antineoplastic*


erlotinib

*N*-(3-éthynylphényl)-6,7-bis(2-méthoxyéthoxy)quinazolin-4-amine  
*antineoplasique*

erlotinib

*N*-(3-etinilfenil)-6,7-bis(2-metoxietoxi)quinazolin-4-amina  
*antineoplásico* $C_{22}H_{23}N_3O_4$ 

183321-74-6




**febuxostatum**

febuxostat 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid  
*xanthine oxidase and xanthine dehydrogenase inhibitor*

febuxostat acide 2-[3-cyano-4-(2-méthylpropoxy)phényl]-4-méthylthiazole-5-carboxylique  
*inhibiteur de la xanthine oxydase et de la xanthine déshydrogénase*

febuxostat ácido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiliazol-5-carboxílico  
*inhibidor de la oxidasa de xantina y la deshidrogenasa de xantina*  
C<sub>16</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub>S 144060-53-7


**felopreptanum**

felopreptan (2S)-3-[2-(3,4-dimethoxyphenyl)ethoxy]-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3,3-diphenylpropanoic acid  
*endothelin receptor antagonist*

félopreptan acide (2S)-3-[2-(3,4-diméthoxyphényl)éthoxy]-2-[(4,6-diméthylpyrimidin-2-yl)oxy]-3,3-diphénylpropanoïque  
*antagoniste du récepteur de l'endothéline*

felopreptán ácido (2S)-3-[2-(3,4-dimetoxifenil)etoxi]-2-[(4,6-dimetilpirimidin-2-il)oxi]-3,3-difenilpropanoico  
*antagonista del receptor de endotelina*


C<sub>31</sub>H<sub>32</sub>N<sub>2</sub>O<sub>6</sub> 204267-33-4

**finafloxacinum**


finafloxacin (-)-8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid  
*antibacterial*

finafloxacin (-)-acide 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique  
*antibactérien*

finafloxacina (-)-ácido 8-ciano-1-ciclopropil-6-fluoro-7-[(4aS,7aS)-hexahidropirrolo[3,4-b]-1,4-oxazin-6(2H)-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico  
*antibacteriano*



209342-40-5

**gadomelitolum**

gadomelitol



hydrogen [2,2',2'',2'''-[1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl]tétrakis=[5-[[[2-[[[4-[[[2-[[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phényl]amino]-2-oxoéthyl]carbamoyl]phényl]=carbamoyl]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]]=gadolate(1-)  
*diagnostic agent*

gadomélitol

hydrogène-[2,2',2'',2'''-[1,4,7,10-tétraazacyclododécane-1,4,7,10-triyl]tétrakis [5-[[[2-[[[4-[[[2-[[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo]carbamoyl]phényl]amino]-2-oxoéthyl]carbamoyl]phényl]=carbamoyl]phényl]amino]-2-oxoéthyl]amino]-5-oxopentanoato](4-)]]=gadolate(1-)  
*produit à usage diagnostique*

gadomelitol

hidrógeno-[2,2',2'',2'''-[1,4,7,10-tetraazacyclododecano-1,4,7,10-triil]tétrakis=[5-[[[2-[[[4-[[[2-[[[3,5-bis[bis[(2S,3R,4R,5R)-2,3,4,5,6-pentahidroxihexil-2,4,6-tribromo]carbamoi]fenil]amino]-2-oxoetil]carbamoi]fenil]carbamoi]fenil]=amino]-2-oxoetil]amino]-5-oxopentanoato](4-)]]=gadolato(1-)  
*agente de diagnóstico*



**garnocestimum**

garnocestim

5-73-macrophage inflammatory protein 2 $\alpha$  (human gene gro2)  
*immunomodulator*

garnocestim

CXC chimiokine GRO $\beta$ -(5-73)-peptide (GRO $\beta$  : protéine inflammatoire humaine  
sécritée par les macrophages)  
*immunomodulateur*

garnocestim

CXC quimiokina GRO $\beta$ -(5-73)-péptido (GRO $\beta$  : protéine inflamatoria humana  
secretada por los macrófagos)  
*immunomodulador*C<sub>325</sub>H<sub>557</sub>N<sub>97</sub>O<sub>95</sub>S<sub>6</sub>

246861-96-1

TELRCQ	CLQTLQGIHL	KNIQSVKVKKS	PGPHCAQTEV
IATLKNGQKA	CLNPASPMVK	KIIEKMLKNG	KSN

**gefitinibum**

gefitinib

*N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine  
*antineoplastique*


géfitinib

*N*-(3-chloro-4-fluorophényl)-7-méthoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine  
*antinéoplasique*

gefitinib

*N*-(3-cloro-4-fluorofenil)-7-metoxi-6-[3-(morfolin-4-il)propoxi]quinazolin-4-amina  
*antineoplásico*C<sub>22</sub>H<sub>24</sub>ClFN<sub>4</sub>O<sub>3</sub>

184475-35-2

**ingliferibum**

ingliferib

5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxyppyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide  
*antidiabetic*


ingliferib

5-chloro-*N*-[(1*S*,2*R*)-1-benzyl-3-(*cis*-3,4-dihydroxyppyrrolidin-1-yl)-2-hydroxy-3-oxopropyl]-1*H*-indole-2-carboxamide  
*antidiabétique*


ingliferib

5-cloro-*N*-[(1*S*,2*R*)-1-bencil-3-(*cis*-3,4-dihidroxippyrrolidin-1-il)-2-hidroxi-3-oxopropil]-1*H*-indol-2-carboxamida  
*antidiabético*





186392-65-4

**ipravacainum**

ipravacaine

(2*RS*)-1-(cyclopropylmethyl)-2',6'-dimethyl-2-piperidinecarboxanilide  
*local anaesthetic*


ipravacaïne

(2*RS*)-1-(cyclopropylméthyl)-*N*-(2,6-diméthylphényl)pipéridine-2-carboxamide  
*anesthésique local*

ipravacaína

(2*RS*)-1-(ciclopropilmetil)-*N*-(2,6-dimetilfenil)piperidina-2-carboxamida  
*anestésico local*

166181-63-1

and enantiomer  
et énantiomère  
y enantiómero**isegananum**

iseganan

L-arginylglycylglycyl-L-leucyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-arginylglycyl-L-arginyl-L-phenylalanyl-L-cysteinyl-L-valyl-L-cysteinyl-L-valylglycyl-L-argininamide cyclic (5→14),(7→12)-bis(disulfide)  
*antibacterial*

iséganan

(5→14),(7→12)-bis(disulfure cyclique) de L-arginyl-glycyl-glycyl-L-leucyl-L-cystéinyl-L-tyrosyl-L-cystéinyl-L-arginyl-glycyl-L-arginyl-L-phénylalanil-L-cystéinyl-L-valyl-L-cystéinyl-L-valyl-glycyl-L-argininamide  
*antibactérien*


iseganán

(5→14),(7→12)-bis(disulfuro cíclico) de L-arginil-glicil-glicil-L-leucil-L-cisteinil-L-tirosil-L-cisteinil-L-arginil-glicil-L-arginil-L-fenilalanil-L-cisteinil-L-valil-L-cisteinil-L-valil-glicil-L-argininamida  
*antibacteriano*



$C_{37}H_{36}N_4O_3$ 

197509-46-9

**lapisteridum**

lapisteride

*N*-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -carboxamide  
5 $\alpha$ -reductase inhibitor

lapist ride


3-(1-benzylpip ridin-4-yl)-1-(2,3,4,5-t trahydro-1*H*-1-benzaz pin-8-yl)propan-1-one  
inhibiteur de la 5 $\alpha$ -r ductase

lapisterida

3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1*H*-1-benzazepin-8-il)propan-1-ona  
inhibidor de la 5 $\alpha$ -reductasa

 $C_{29}H_{40}N_2O_3$ 

142139-60-4

**laquinimodum**

laquinimod

5-chloro-*N*-ethyl-4-hydroxy-1-methyl-2-oxo-*N*-phenyl-1,2-dihydroquinoline-3-carboxamide  
immunomodulator

laquinimod


5-chloro-*N*- thyl-4-hydroxy-1-m thyl-2-oxo-*N*-ph nyl-1,2-dihydroquinol ine-3-carboxamide  
immunomodulateur

laquinimod

5-cloro-*N*-etil-4-hidroxi-1-metil-2-oxo-*N*-fenil-1,2-dihidroquinolina-3-carboxamida  
immunomodulador

$C_{19}H_{17}ClN_2O_3$ 

248281-84-7

**laronidasum**

laronidase

8-L-histidine-a-L-iduronidase (human)  
*enzyme*

laronidase

[8-L-histidine]-a-L-iduronidase humaine  
*enzyme*

laronidasa

8-L-histidina-a-L-iduronidasa (humano)  
*enzima* $C_{3169}H_{4854}N_{901}O_{884}S_{12}$ 

210589-09-6

AEAPHLVHVD	AARALWPLRR	FWRSTGFCPP	LPHSQADQYV
LSWDQQLNLA	YVGAVPHRGI	KQVRTHWLE	LVTTRGSTGR
GLSYN <sup>*</sup> FTHLD	GYLDLLRENQ	LLPGFELMGS	ASGHFTDFED
KQQVFEWKDL	VSSLARRYIG	RYGLAHVSKW	NFETWNEPDH
HDFD <sup>*</sup> NVSM <sup>*</sup> TM	QGFLNYYDAC	SEGLRAASPA	LRLGGPGDSF
HTPPRSPLSW	GLLRHCHDGT	NFFTGEAGVR	LDYISLHRKG
ARSSISILEQ	EKVVAQQIRQ	LFPKFADTPI	YNDEADPLVG
WSLPQPWRAD	VTYAAMVVKV	IAQHQNLLLA	<sup>*</sup> NTTSAFPYAL
LSNDNAFLSY	HPHPFAQRTL	TARFQV <sup>*</sup> NNTR	PPHVQLLRKP
VL <sup>*</sup> TAMGLLAL	LDEEQLWAEV	SQAGTVLDS <sup>*</sup> N	HTVGVLASAH
RPQGPADAWR	AAVLIYASDD	TRAHP <sup>*</sup> NRSVA	VTLRLRGVPP
G <sup>*</sup> PGLVYVTRY	LDNGLCSPDG	EW <sup>*</sup> RRLGRPVF	PTAEQFRRMR
AAEDPVAAAP	RPLPAGGRLT	LRPALRLPSL	LLVHVCARPE
KPPGQVTRLR	ALPLTQGQLV	LVWSDEHVGS	KCLW <sup>*</sup> TYEIQF
SQDGKAYTPV	SRKPSTFNLF	VFSPDTGAVS	GSYRVRALDY
WARPGPFSDP	VPYLEVPVPR	GPPSPGNP	

\* : glycosylation sites / sites de glycosylation / posiciones de glicosilación



↳ : disulfide / disulfure / disulfuro

**lirimilastum**

lirimilast 2-(2,4-dichlorobenzoyl)-3-ureidobenzofuran-6-yl methanesulfonate  
*antiasthmatic*

lirimilast méthanesulfonate de 2-(2,4-dichlorobenzoyl)-3-uréidobenzofuran-6-yle  
*antiasthmatique*

lirimilast metanesulfonato de 2-(2,4-diclorobenzoil)-3-ureidobenzofuran-6-ilo  
*antiasmático*

**livaraparinum calcium**

livaraparin calcium calcium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-O-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-structure at the reducing end of their chain; the mass-average molecular mass ranges between 3000 and 5000 with 75% is less than 8000; the degree of sulfatation is approximately 2 per disaccharidic unit  
*anticoagulant*

livaraparine calcique sel calcique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc ; la majorité des composants de la livaraparine calcique possèdent une structure acide 2-O-sulfo- $\alpha$ -L-idopyranosuronique à l'extrémité non réductrice de leur chaîne et une structure 6-O-sulfatée à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne est de 3000 à 5000, 75% étant inférieure à 8000 ; le degré de sulfatation par unité disaccharide est voisin de 2  
*anticoagulant*

livaraparina cálcica sal cálcica de una heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización con ácido nitroso; la mayoría de los componentes de la livaraparina cálcica tienen ácido 2-O-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor de la cadena y una estructura 6-O-sulfatada en el extremo reductor de la cadena; la masa molecular relativa media es de 3000 a 5000, siendo el 75% inferior a 8000; el grado de sulfatación por unidad de disacárido es aproximadamente 2  
*anticoagulante*

**manifaxinum**


manifaxine (2*S*,3*S*,5*R*)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol  
*antidepressant*

manifaxine (2*S*,3*S*,5*R*)-2-(3,5-difluorophényl)-3,5-diméthylmorpholin-2-ol  
*antidépresseur*

manifaxina (2*S*,3*S*,5*R*)-2-(3,5-difluorofenil)-3,5-dimetilmorfolin-2-ol  
*antidepresivo*

$C_{12}H_{15}F_2NO_2$

135306-39-7

**miglustatum**


miglustat (2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol  
*glucosyltransferase inhibitor*

miglustat (2*R*,3*R*,4*R*,5*S*)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol  
*inhibiteur de la glucosyltransférase*

miglustat (2*R*,3*R*,4*R*,5*S*)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol  
*inhibidor de la glucosil transferasa*

$C_{10}H_{21}NO_4$

72599-27-0

**miriplatinum**


miriplatin (SP-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N,N'*]=  
bis(tetradecanoato-*O*)platino  
*antineoplastic*

miriplatine (SP-4-2)-[(1*R*,2*R*)-cyclohexane-1,2-diamine-*N,N'*]=  
bis(tétradécanoato-*O*)platine  
*antinéoplasique*

miriplatino (SP-4-2)-[(1*R*,2*R*)-ciclohexano-1,2-diamina-*N,N'*]=  
bis(tetradecanoato-*O*)platino  
*antineoplásico*

$C_{34}H_{68}N_2O_4Pt$ 

141977-79-9

**mirostipenum**

mirostipen

[23-methionine]human myeloid progenitor inhibitory factor 1-(23-99)-peptide  
*myeloprotectant*


mirostipen

[23-méthionine]facteur 1 d'inhibition du précurseur myéloïde humain-(23-99)-peptide  
*protecteur des cellules hématopoiétiques*

mirostipeno

[23-metionina]-(23-99)-péptido del factor 1 de inhibición del progenitor mieloide humano  
*mieloprotector* $C_{380}H_{614}N_{112}O_{113}S_9$ 

244130-01-6

**mureletecanum**

mureletecan


poly[[N-(2-hydroxypropyl)methacrylamide]-co-[camptothecin ester with N-[6-(2-methacrylamidoacetamido)hexanoyl]glycine]-co-[N-[(2-hydroxypropyl)carbamoyl]methyl]methacrylamide]]  
*antineoplastic*

murélétecán

copolymère de N-[(2RS)-2-hydroxypropyl]-2-méthylpropénamide, de N-[2-[[6-[[[2-[[[(4S)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-4-yl]oxy]-2-oxoéthyl]amino]-6-oxohexyl]amino]-2-oxoéthyl]-2-méthylpropénamide et de N-[2-[[[(2RS)-2-hydroxypropyl]amino]-2-oxoéthyl]-2-méthylpropénamide  
*antineoplasique*

mureletecán

poli[[N-(2-hidroxiopropil)metacrilamida]-co-éster de camptotecina con N-[6-(2-metacrilamidoacetamido)hexanoil]glicina]-co-[N-[(2-hidroxiopropil)carbamoil]metil]metacrilamida]]  
*antineoplásico*

**nasaruplasum beta**

nasaruplase beta

prourokinase (enzyme-activating) human (clone pUK4/pUK18 protein moiety),  
glycosylated (murine cell line SP2/0)  
*enzyme*


nasaruplase bêta

prourokinase (activateur d'enzyme) humaine glycosylée dont le gène est  
cloné dans le vecteur pUK4/pUK18 et exprimée dans la lignée cellulaire  
murine SP2/0  
*enzyme*

nasaruplase beta

prourokinasa (activador de enzima) (fracción proteica obtenida del clon  
humano pUK4/pUK18), glicosilada  
*enzima*





136653-69-5

```

SNELHQVPSN  CDCLNGGTCV  SNKYFSNIHW  CNCPKKFGGQ
HCEIDKSKTC  YEGNGHFYRG  KASTDTMGRP  CLPWNSATVL
QQTYHAHRSD  ALQLGLGKHN  YCRNPDNRRR  PWCYVQVGLK
PLVQECMVHD  CADGKKPSSP  PEELKFQCGQ  KTLRPRFKII
GGEFTTIENQ  PWFAAIYRRH  RGGSVTYVCG  GSLISPCWVI
SATHCFIDYP  KKEDYIVYLG  RSRLNSNTQG  EMKFEEVNL
LHKDYSADTL  AHNDIALLK  IRSKEGRCAQ  PSRTIQITICL
PSMYNDPQFG  TSCEITGFGK  ENSTDYLYPE  QLKMTVVKLI
SHRECQQPHY  YGSEVTTKML  CAADPQWKTD  SCQGDSSGGL
VCSLQGRMTL  TGIVSWGRC  ALKDKPGVYT  RVSHFLPWIR
SHTKEENGLA  L

```

\* : glycosylation sites / sites de glycosylation / posiciones de glicosilación

**netoglitazonum**

netoglitazone

(5*RS*)-5-[[6-[(2-fluorophenyl)methoxy]naphthalen-2-yl]methyl]thiazolidine-2,4-dione  
*antidiabetic*

nétoglitazone


(5*RS*)-5-[[6-[(2-fluorophényl)méthoxy]naphtalén-2-yl]méthyl]thiazolidine-2,4-dione  
*antidiabétique*

netoglitazona

(5*RS*)-5-[[6-[(2-fluorofenil)metoxi]naftalen-2-il]metil]tiazolidina-2,4-diona  
*antidiabético*



161600-01-7



and enantiomer  
et énantiomère  
y enantiómero

**ospemifenum**

ospemifene

2-[*p*-[(*Z*)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]ethanol  
*antiestrogen*


ospémifène

(Z)-2-[4-(4-chloro-1,2-diphénylbut-1-ényl)phénoxy]éthanol  
*antiœstrogène*

ospemifeno

2-[*p*-[(*Z*)-4-cloro-1,2-difenil-1-butenil]fenoxi]etanol  
*antiestrógeno* $C_{24}H_{23}ClO_2$ 

128607-22-7

**pegfilgrastimum**

pegfilgrastim

*N*-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with  
 $\alpha$ -methyl- $\omega$ -hydroxypoly(oxyethylene)  
*immunomodulator*


pegfilgrastim

*N*-(3-hydroxypropyl)méthionylfacteur de stimulation de colonie humain,  
1-éther avec le  $\alpha$ -méthyl- $\omega$ -hydroxypoly(oxyéthylène)  
*immunomodulateur*

pegfilgrastim

*N*-(3-hydroxypropyl)methionyl(human colony-stimulating factor), 1-ether with  
 $\alpha$ -methyl- $\omega$ -hydroxypoly(oxy-1,2-ethanediyl)  
*inmunomodulador* $C_{849}H_{1348}N_{223}O_{244}S_9(C_2H_4O)_n$ 

208265-92-3



TPLGPASSLP	QSFLKCLEQ	VRKIQQDGAA	LQEKLCATYK
LCHPEELVLL	GHSLGIPWAP	LSSCPSQALQ	LAGCLSQ LHS
GLFLYQGLLQ	ALEGISPELG	PTLDTLQLDV	ADFATTIWQQ
MEELGMAPAL	QPTQGAMPAF	ASAFQRRAGG	VLVASHLQSF
LEVSYRVLRH	LAQP		

**pexelizumabum**

pexelizumab

immunoglobulin, anti-(human complement C5  $\alpha$ -chain) (human-mouse monoclonal 5G1.1-SC single chain)  
*immunomodulator*

pexélizumab

immunoglobuline, anti-(chaîne- $\alpha$  du complément C5 humain) (mono chaîne de l'anticorps monoclonal de souris humanisé 5G1.1-SC)  
*immunomodulateur*

pexelizumab

inmunoglobulina, anti-(cadena- $\alpha$  de complemento C5 humano) (mono cadena del anticuerpo monoclonal humanizado de ratón 5G1.1-SC)  
*inmunomodulador*

219685-93-5

**pralnacasanum**

pralnacasan

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-ethoxy-5-oxotetrahydrofuran-3-yl]-9-[(isoquinolin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*][1,2]=diazepine-1-carboxamide  
*enzyme*


pralnacasan

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-éthoxy-5-oxotétrahydrofuran-3-yl]-9-[(isoquinoléin-1-ylcarbonyl)amino]-6,10-dioxooctahydro-6-*H*-pyridazino[1,2-*a*]=[1,2]diazépine-1-carboxamide  
*enzyme*

pralnacasán

(1*S*,9*S*)-*N*-[(2*R*,3*S*)-2-etoxi-5-oxotetrahidrofuran-3-il]-9-[(isoquinolin-1-ilcarbonyl)amino]-6,10-dioxooctahidro-6-*H*-piridazino[1,2-*a*][1,2]diazepina-1-carboxamida  
*enzima*  
C<sub>28</sub>H<sub>29</sub>N<sub>5</sub>O<sub>7</sub>

192755-52-5



**prazosartanum**

prazosartan

2-propyl-3-[[2'-(1*H*-tetrazol-5-yl)biphenyl-4-yl]methyl]-5,6,7,8-tetrahydrocycloheptaimidazol-4(3*H*)-one  
*angiotensin II receptor antagonist*

prazosartan


2-propyl-3-[[2'-(1*H*-tétrazol-5-yl)biphényl-4-yl]méthyl]-5,6,7,8-tétrahydrocycloheptaimidazol-4(3*H*)-one  
*antagoniste du récepteur de l'angiotensine II*

prazosartán

2-propil-3-[[2'-(1*H*-tetrazol-5-il)bifenil-4-il]metil]-5,6,7,8-tetrahidrocicloheptaimidazol-4(3*H*)-ona  
*antagonista del receptor de angiotensina II*

C<sub>25</sub>H<sub>26</sub>N<sub>6</sub>O

153804-05-8

**ragaglitazarum**

ragaglitazar

(-)-(2*S*)-2-ethoxy-3-[4-[2-(10*H*-phenoxazin-10-yl)ethoxy]phenyl]propanoic acid  
*antidiabetic*

ragaglitazar


(-)-acide (2*S*)-2-éthoxy-3-[4-[2-(10*H*-phénoxazin-10-yl)éthoxy]phényl]=propanoïque  
*antidiabétique*

ragaglitazar

(-)-ácido (2*S*)-2-etoxi-3-[4-[2-(10*H*-fenoxazin-10-il)etoxi]fenil]propanoico  
*antidiabético*

C<sub>25</sub>H<sub>25</sub>NO<sub>5</sub>

222834-30-2



**reminertantum**

reminertant

2-[[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1<sup>3,7</sup>]decane-2-carboxylic acid  
*neurotensin antagonist*

réminertant


acide 2-[[[1-(7-chloroquinoléin-4-yl)-5-(2,6-diméthoxyphényl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1<sup>3,7</sup>]décane-2-carboxylique  
*antagoniste de la neurotensine*

reminertant

ácido 2-[[[1-(7-cloroquinolin-4-il)-5-(2,6-dimetoxifenil)-1H-pirazol-3-il]carbonil]amino]triciclo[3.3.1.1<sup>3,7</sup>]decano-2-carboxílico  
*antagonista de la neurotensina*

C<sub>32</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>5</sub>

146362-70-1

**reslizumabum**

reslizumab

immunoglobulin G4, anti-(human interleukin 5) (human-rat monoclonal SCH 55700  $\gamma$ 4-chain), disulfide with human-rat monoclonal SCH 55700 light chain, dimer  
*immunomodulator*

reslizumab

immunoglobuline G4, anti-(interleukine 5 humaine ), (chaîne  $\gamma$ 4 de l'anticorps monoclonal de rat humanisé SCH 55700), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat humanisé SCH 55700  
*immunomodulateur*

reslizumab

immunoglobulina G4, anti-(interleukina 5 humana ), (cadena  $\gamma$ 4 del anticuerpo monoclonal humanizado de rata SCH 55700), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de rata SCH 55700  
*inmunomodulador*

241473-69-8

**ruboxistaurinum**

ruboxistaurin

(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,19H-5,21:12,17-dimethenodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-18,20-dione  
*PKC  $\alpha$  inhibitor*

ruboxistaurine


(9S)-9-[(diméthylamino)méthyl]-6,7,10,11-tétrahydro-9H,19H-5,21:12,17-diméthénodibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadécène-18,20-dione  
*inhibiteur de l'isoforme  $\beta$  de la protéinekinase C*

ruboxistaurina

(9S)-9-[(dimetilamino)metil]-6,7,10,11-tetrahidro-9H,19H-5,21:12,17-dimetenodibenzo[e,k]pirrolo[3,4-h][1,4,13]oxadiazaciclohexadeceno-18,20-diona  
*inhibidor de la PKC*

C<sub>28</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>

169939-94-0

**semaxanibum**

semaxanib

3-[(Z)-(3,5-dimethylpyrrol-2-yl)methylene]-2-indolinone  
*antineoplastic*

sémaxanib


(Z)-3-[(3,5-diméthyl-1H-pyrrol-2-yl)méthylène]-1,3-dihydro-2H-indol-2-one  
*antineoplasique*

semaxanib

3-[(Z)-(3,5-dimetilpirrol-2-il)metileno]-2-indolinona  
*antineoplásico*

C<sub>15</sub>H<sub>14</sub>N<sub>2</sub>O

194413-58-6



**senazodanum**


senazodan 6-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydropyridazin-3(2H)-one  
*cardiac stimulant*

sénazodan 6-[4-(pyridin-4-ylamino)phényl]-4,5-dihydropyridazin-3(2H)-one  
*cardiotonique*

senazodán 6-[4-(piridin-4-ilamino)fenil]-4,5-dihidropiridazin-3(2H)-ona  
*cardiotónico*

C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O

98326-32-0

**silodosinum**


silodosin (-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]=ethyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide  
*α<sub>1a</sub>-adrenoreceptor antagonist*

silodosine (-)-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroéthoxy)phénoxy]=éthyl]amino]propyl]-2,3-dihydro-1H-indole-7-carboxamide  
*antagoniste α<sub>1a</sub>-adrénergique*

silodosina (-)-1-(3-hidroxipropil)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroetoxi)fenoxi]etil]=amino]propil]-2,3-dihidro-1H-indol-7-carboxamida  
*antagonista de los receptores α<sub>1a</sub>-adrenérgicos*

C<sub>25</sub>H<sub>32</sub>F<sub>3</sub>N<sub>3</sub>O<sub>4</sub>

160970-54-7



**solifenacinum**

solifenacin


(3*R*)-1-azabicyclo[2.2.2]oct-3-yl (1*S*)-1-phenyl-3,4-dihydroisoquinoline-2(1*H*)-carboxylate  
*muscarin receptor antagonist*

solifénacine

(1*S*)-1-phényl-3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de  
 (3*R*)-1-azabicyclo[2.2.2]oct-3-yle  
*antagoniste des récepteurs de la muscarine*

solifenacina

(1*S*)-1-fenil-3,4-dihidroisoquinolina-2(1*H*)-carboxilato de  
 (3*R*)-1-azabicyclo[2.2.2]oct-3-ilo  
*antagonista de los receptores de la muscarinicos*  
 $C_{23}H_{26}N_2O_2$  242478-37-1

**tadalafilum**

tadalafil

(6*R*,12*aR*)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12*a*-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione  
*vasodilator*

tadalafil


(6*R*,12*aR*)-6-(1,3-benzodioxol-5-yl)-2-méthyl-2,3,6,7,12,12*a*-hexahydropyrazino[1',2':1,6]pyrido[3,4-*b*]indole-1,4-dione  
*vasodilateur*

tadalafilo

(6*R*,12*aR*)-6-(1,3-benzodioxol-5-il)-2-metil-2,3,6,7,12,12*a*-hexahidropirazino[1',2':1,6]pirido[3,4-*b*]indol-1,4-diona  
*vasodilatador*

 $C_{22}H_{19}N_3O_4$ 

171596-29-5





**tafluposidum**

tafluposide


4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-éthylidène]-2,3-bis-*O*-[(pentafluorophénoxy)acétyl]-β-*D*-glucopyranosyl]oxy]-6-oxo-5,5*a*,6,8,8*a*,9-hexahydrofuro[3',4':6,7]naphtho[2,3-*d*]-1,3-dioxol-5-yl]-2,6-diméthoxyphényle dihydrogen phosphate  
*cytostatic*

tafluposide


dihydrogénophosphate de 4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-éthylidène]-2,3-bis-*O*-[(pentafluorophénoxy)acétyl]-β-*D*-glucopyranosyl]oxy]-6-oxo-5,5*a*,6,8,8*a*,9-hexahydrofuro[3',4':6,7]naphtho[2,3-*d*]-1,3-dioxol-5-yl]-2,6-diméthoxyphényle  
*cytostatique*

taflupósido

dihidrógenofosfato de 4-[(5*R*,5*aR*,8*aR*,9*S*)-9-[[4,6-*O*-[(1*R*)-etilideno]-2,3-bis-*O*-[(pentafluorofenoxi)acetil]-β-*D*-glucopiranosil]oxi]-6-oxo-5,5*a*,6,8,8*a*,9-hexahidrofuro[3',4':6,7]nafto[2,3-*d*]-1,3-dioxol-5-il]-2,6-dimetoxifenilo  
*citostático*



179067-42-6

**telberminum**

telbermin


vascular endothelial growth factor (human), dimer  
*angiogene*

telbermine


facteur de croissance de l'endothélium vasculaire humain (dimère)  
*angiogène*

telbermina

factor de crecimiento del endotelio vascular (humano), dímero  
*factor angiogénico*



205887-54-3



↪ : disulfide / disulfure / disulfuro

**tenivastatinum**

tenivastatin

(3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8*a*-hexahydronaphtalen-1-yl]-3,5-dihydroxyheptanoic acid  
*antihyperlipidaemic*

ténivastatine


acide (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-diméthylbutanoyl)oxy]-2,6-diméthyl-1,2,6,7,8,8*a*-hexahydronaphtalén-1-yl]-3,5-dihydroxyheptanoïque  
*antihyperlipidémiant*

tenivastatina

ácido (3*R*,5*R*)-7-[(1*S*,2*S*,6*R*,8*S*,8*aR*)-8-[(2,2-dimetilbutanoil)oxi]-2,6-dimetil-1,2,6,7,8,8*a*-hexahidronaftalen-1-il]-3,5-dihidroxiheptanoico  
*antihiperlipémico*



121009-77-6



**tesaglitazarum**

tesaglitazar

(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]=  
propanoic acid  
*antidiabetic*

tésaglitazar


acide (2S)-2-éthoxy-3-[4-[2-[4-[(méthylsulfonyl)oxy]phényl]éthoxy]phényl]=  
propanoïque  
*antidiabétique*

tesaglitazar

ácido (2S)-2-etoxi-3-[4-[2-[4-[(metilsulfonil)oxi]fenil]etoxi]fenil]propanoico  
*antidiabético*

C<sub>20</sub>H<sub>24</sub>O<sub>7</sub>S

251565-85-2

**tofimilastum**

tofimilast

9-cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-  
1,2,4-triazolo[4,3-a]pyridine  
*antiasthmatic*

tofimilast


9-cyclopentyl-7-éthyl-3-(thiophén-2-yl)-6,9-dihydro-5H-pyrazolo[3,4-c]-  
1,2,4-triazolo[4,3-a]pyridine  
*antiasthmaticque*

tofimilast

9-ciclopentil-7-etil-3-(tiofen-2-il)-6,9-dihidro-5H-pirazolo[3,4-c]-  
1,2,4-triazolo[4,3-a]piridina  
*antiasmático*

C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>S

185954-27-2



**xidecaflurum**

xidecaflur

2,2 -[(9Z)-9-octadecenylimino]diethanol hydrofluoride  
*dental product, anticaries*


xidécaflur

fluorhydrate de 2,2'-[(9Z)-octadec-9-énylimino]diéthanol  
*prophylaxie des caries dentaires*

xidecaflur

hidrofluoruro de 2,2 -[(9Z)-9-octadecenilimino]diethanol  
*producto dental anticaries* $C_{22}H_{46}FNO_2$ 

207916-33-4

**zanapezilum**

zanapezil

3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)propan-1-one  
*nootropic agent*


zanapézil

3-(1-benzylpipéridin-4-yl)-1-(2,3,4,5-tétrahydro-1H-1-benzazépin-8-yl)propan-1-one  
*nootrope*

zanapezilo

3-(1-bencilpiperidin-4-il)-1-(2,3,4,5-tetrahidro-1H-1-benzazepin-8-il)propan-1-ona  
*nootropo* $C_{25}H_{32}N_2O$ 

142852-50-4



**zonampanelum**


zonampanel [7-(1*H*-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2*H*)-yl]acetic acid  
*AMPA receptor antagonist*

zonampanel acide [7-(1*H*-imidazol-1-yl)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2*H*)-yl]acétique  
*antagoniste des récepteurs de l'AMPA*

zonampanel ácido [7-(1*H*-imidazol-1-il)-6-nitro-2,3-dioxo-3,4-dihydroquinoxalin-1(2*H*)-il]acético  
*antagonista de los receptores de AMPA*

C<sub>13</sub>H<sub>9</sub>N<sub>5</sub>O<sub>6</sub>

210245-80-0

**zoniporidum**


zoniporide *N*-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1*H*-pyrazole-4-carboxamide  
*Na<sup>+</sup>/H<sup>+</sup> antiport inhibitor*

zoniporide *N*-carbamimidoyl-5-cyclopropyl-1-(quinoléin-5-yl)-1*H*-pyrazole-4-carboxamide  
*inhibiteur de l'échange Na<sup>+</sup>/H<sup>+</sup>*

zoniporida *N*-carbamimidoil-5-ciclopropil-1-(quinolin-5-il)-1*H*-pyrazol-4-carboxamida  
*inhibidor del transporte activo Na<sup>+</sup>/H<sup>+</sup>*

C<sub>17</sub>H<sub>16</sub>N<sub>6</sub>O

241800-98-6



**zoticasonum**

zoticasone


S-[(3*R*)-2-oxotétrahydrofuran-3-yl] 6á,9-difluoro-12â,17-dihydroxy-16á-méthyl-3-oxoandrosta-1,4-diène-17â-carbothioate  
*corticostéroide*

zoticasone

6á,9-difluoro-12â,17-dihydroxy-16á-méthyl-3-oxoandrosta-1,4-diène-17â-carbothioate de S-[(3*R*)-2-oxotétrahydrofuran-3-yle]  
*corticostéroide*

zoticasona

6á,9-difluoro-12â,17-dihidroxi-16á-metil-3-oxoandrosta-1,4-dieno-17â-carbotioato de S-[(3*R*)-2-oxotetrahidrofuran-3-ilo]  
*corticosteroide*

 $C_{25}H_{30}F_2O_6S$ 

---

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Proposed International Nonproprietary Names (Prop. INN): List 59**

**Dénominations communes internationales proposées (DCI Prop.): Liste 59**

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 59**

*(WHO Drug Information/Informations pharmaceutiques OMS/Informaciones farmaceuticas de la OMS, Vol. 2, No. 2, 1988)*

p. 16 *delete/supprimer/suprimase*                      *insert/insérer/insértese*

**levoglutamidum**

levoglutamide

lévoglutamide

levoglutamida

**glutaminum**

glutamine

glutamine

glutamina

**Proposed International Nonproprietary Names (Prop. INN): List 80**

**Dénominations communes internationales proposées (DCI Prop.): Liste 80**

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 80**

*(WHO Drug Information, Vol. 12, No. 4, 1998)*

*suprimase*

*insértese*

p. 255 carabersato

carabersat

p. 280 tonabersato

tonabersat

**Proposed International Nonproprietary Names (Prop. INN): List 82**

**Dénominations communes internationales proposées (DCI Prop.): Liste 82**

**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 82**

*(WHO Drug Information, Vol. 13, No. 4, 1999)*

p. 264 **adalimumabum**

adalimumab

*sustitúyase la descripción por la siguiente:*

inmunoglobulina G1 (anti-factor  $\alpha$  de necrosis tumoral humano) (cadena pesada del anticuerpo monoclonal humano D2E7), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo D2E7 monoclonal humano

p. 266 **amiglumidum**

amiglumida

*sustitúyase la descripción por la siguiente:*

ácido (*R*)-4-(2-naftamido)-*N,N*-dipentilglutarámico

p. 274 **evernimicinum**

evernimicina

*sustitúyase la descripción por la siguiente:*

O-3-C-metil-4-O-metil-3-nitro-2,3,6-tridesoxi- $\alpha$ -L-*arabino*-hexopiranosil-(1 $\rightarrow$ 3)-O-4-O-(3,5-dicloro-4-hidroxi-2-metoxi-6-metilbenzoil)-2,6-didesoxi- $\alpha$ -D-*arabino*-hexopiranosil-(1 $\rightarrow$ 4)-O-(1R)-2,6-didesoxi-D-*arabino*-hexopiranosilideno-(1 $\rightarrow$ 3-4)-O-3-C-metil-6-desoxi- $\alpha$ -D-manopiranosil-(1 $\rightarrow$ 3)-O-4-O-metil-6-desoxi- $\alpha$ -D-galactopiranosil-(1 $\rightarrow$ 4)-2,6-di-O-metil- $\alpha$ -D-manopiranosido de O-(1R)-4-O-(2,4-dihidroxi-6-metilbenzoil)-2,3-O-metileno-D-xilopiranosilideno-(1 $\rightarrow$ 3-4)- $\alpha$ -L-lixopiranosilo

p. 278 **irolfulvenum**

irolfulveno

*sustitúyase la descripción por la siguiente:*

(R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilespiro[ciclopropano-1,5'-[5H]inden]-7'(6'H)-ona

p. 281 *delete/supprimer/suprimase**insert/insérer/insértese***nebostinelum**

nebostinel  
nébostinel  
nebostinel

**neboglaminum**

neboglamine  
néboglamine  
neboglamina

p. 282 **onerceptum**

onercept

*replace the description by the following:*

TNF-BP-(20-180)-peptide (part of extracellular domain of the glycosylated human Tumor Necrosis Factor Receptor 1)

onercept

*sustitúyase la descripción por la siguiente:*

péptido (20-180) TNF-BP (parte del dominio extracelular del receptor 1 humano del factor de necrosis tumoral glicosiladoo)

p. 284 **posaconazolum**

posaconazol

*sustitúyase la descripción por la siguiente:*

4-[p-[4-[p-[[[(3R,5R)-5-(2,4-difluorofenil)tetrahidro-5-(1H)-1,2,4-triazol-1-ilmetil]-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1S,2S)-1-etil-2-hidroxiopropil]- $\text{\AA}$ <sup>2</sup>-1,2,4-triazolin-5-ona




---

**Proposed International Nonproprietary Names (Prop. INN): List 83**  
**Dénominations communes internationales proposées (DCI Prop.): Liste 83**  
**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 83**  
*(WHO Drug Information, Vol. 14, No. 2, 2000)*

p. 129 **rosuvastatinum**

rosuvastatin	<i>replace the molecular formula by the following:</i>
rosuvastatine	<i>remplacer la formule brute par:</i>
rosuvastatina	<i>sustitúyase la fórmula molecular por:</i>



*replace the CAS registry number by the following:*  
*remplacer le numéro dans le registre du CAS par:*  
*sustitúyase le numéro dans le registre du CAS por:*

287714-14-4

**Proposed International Nonproprietary Names (Prop. INN): List 84**  
**Dénominations communes internationales proposées (DCI Prop.): Liste 84**  
**Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 84**  
*(WHO Drug Information, Vol. 14, No. 4, 2000)*

p. 267 **sabiporidum**

sabiporide	<i>replace the CAS registry number by the following:</i>
sabiporide	<i>remplacer le numéro dans le registre du CAS par:</i>
sabiporida	<i>sustitúyase le numéro dans le registre du CAS por:</i>

324758-66-9